ABIVAX is trading at €81.10, up 4.04%, amid a biotech-sector rally; no confirmed ABIVAX-specific announcement explaining the October 20 move surfaced.
- The company’s obefazimod presentations at UEG Week were scheduled for October 20, but available coverage does not establish them as the cause.
- The supplied sector update reports XBI up 2.10%, alongside M&A activity and positive clinical-trial sentiment.